Molecular Characterization of the Humoral Responses to Cryptococcus neoformans Infection and Glucuronoxylomannan-Tetanus Toxoid Conjugate Immunization

By Jean Mukherjee,* Arturo Casadevall,† and Matthew D. Scharff*

From the Departments of *Cell Biology and †Medicine, Division of Infectious Diseases, and the Department of Immunology and Microbiology, Albert Einstein College of Medicine, Bronx, New York 10461

Summary

The molecular characteristics of the humoral immune response to a serotype A Cryptococcus neoformans infection were compared with the response elicited by a cryptococcal glucuronoxylomannan–tetanus toxoid (GXM-TT) conjugate. Anticryptococcal monoclonal antibodies (mAbs) isolated from both responses have previously been shown to recognize the same antigenic determinant of cryptococcal GXM. Southern blot and sequence analyses indicate that the hybridomas isolated from each response arose from only a few precursor B cells. All the mAbs generated from the infected and GXM-TT conjugate-immunized mice utilize the same V<sub>H</sub>7183 family member: J<sub>2</sub>/J<sub>4</sub>, v<sub>5.1</sub>, and J<sub>1</sub>; mAbs generated by different B cells had complementarity-determining region 3's (CDR3s) composed of seven amino acids with a common sequence motif. Thus, the molecular analysis of these anticryptococcal mAb-producing hybridomas indicated that the response to both cryptococcal infection and conjugate immunization was oligoclonal and highly restricted with regard to immunoglobulin gene utilization. The GXM-TT conjugate primarily stimulated isotype switching and clonal proliferation, and did not result in hybridomas expressing additional immunoglobulin repertoires. The mAbs from both responses had a number of replacement mutations at the 5' end of CDR2 that appear to be the result of antigen-driven selection. Somatic mutation also resulted in altered epitope specificity for one mAb, 13F1. Passive administration of representative mAbs from different clones generated in response to the GXM-TT conjugate prolonged survival of lethally infected mice.

Cryptococcus neoformans is a ubiquitous organism that is a potential opportunistic pathogen of immunocompromised individuals (1). In recent years cryptococcal infections have become an increasing problem for AIDS patients (2). The major determinant of C. neoformans virulence (3) is a capsule composed of a polysaccharide that accumulates in body fluids and tissues during cryptococcal infection (4, 5). C. neoformans has been divided into five serotypes (A, B, C, D, and AD) (6, 7), each of which exhibits structural differences within the glucuronoxylomannan (GXM)<sup>1</sup> component of the capsular polysaccharide (8–14). Infected individuals rarely have detectable anticryptococcal antibodies (1). Unresponsiveness to cryptococcal infection and immunization with purified C. neoformans capsular polysaccharide (CNPS) has been attributed to immune paralysis, which is probably mediated by T suppressor cells (15, 16). Moreover, purified CNPS is a T cell–independent (TI) type 2 antigen (16, 17) and does not induce Th cell–mediated amplification of the humoral immune response. In addition, we have shown that the ~5% of mice that produce antibodies during infection with clinical isolate mount a very restricted antibody response with respect to isotype, Ig variable gene utilization, and clonal proliferation (18).

There is considerable evidence that anti-CNPS antibodies contribute to host defense. Such antibodies enhance fungistasis by NK cells (19, 20), promote phagocytosis by macrophages (21, 22) and peripheral blood monocytes (23), and facilitate fungal killing by PBMC (24). Patients with cryptococcosis have a more favorable prognosis if serum anticryptococcal antibodies are present (25). Moreover, AIDS patients lack CNPS-specific IgG, suggesting that a deficiency in antibody immunity may contribute to their marked susceptibility (26). Although purified CNPS is a poor immunogen, conjugates composed of CNPS components and protein carriers have been developed as potential vaccines to stimulate antibody

---

1 Abbreviations used in this paper: aka, apparent affinity constant; CNPS, Cryptococcus neoformans capsular polysaccharide; GXM, glucuronoxylomannan; R/S, replacement/silent; TD, T cell dependent; TI, T cell independent; TT, tetanus toxoid.
production (12, 27–29). In addition, passive administration of certain mAbs (30, 31) or polyvalent sera (32, 33) prolong survival of lethally infected mice. mAbs have also been shown to improve the efficacy of amphotericin B (34, 35). However, not all antibodies are equally protective (31, 36, 37). Identification of beneficial antibodies and their characteristics is important for determining whether such antibodies are generated in response to conjugate vaccines.

We recently reported the isolation of six IgMk mAbs from a serotype A C. neoformans–injected BALB/c mouse, and eight IgMk, nine IgGk, and four IgAk mAbs from a BALB/c mouse immunized with a T cell–dependent (TD) serotype A GXM–tetanus toxoid (GXM-TT) conjugate (38). These mAbs all recognize a common antigenic determinant present on the GXM of the four serotypes of CNPS (38). By determining the primary nucleotide structure of these anti-CNPS mAbs, we have been able to compare the basic antibody structures and gene usage of specific mAbs generated in response to CNPS present during cryptococcal infection and GXM-TT immunization. Examination of the Ig gene rearrangement patterns and CDR3 sequences has enabled us to also determine the clonal origins of the B cells that participated in response to CNPS during infection and immunization with the GXM-TT conjugate. Our results provide insight into the B cell response to cryptococcal antigens and are of fundamental importance with regard to vaccine design and passive mAb therapy of cryptococcosis.

Materials and Methods

C. neoformans Strains and Polysaccharides. Serotype A (strain 24064) and D (strain 24067) C. neoformans were obtained from the American Type Culture Collection (ATCC; Rockville, MD). These strains were maintained on Sabouraud's dextrose agar (Difco Laboratories, Detroit, MI) at 4°C and grown with moderate shaking at 37°C in Sabouraud's dextrose broth (Difco Laboratories). CNPS was isolated as described (3).

Hybridomas and mAbs. Hybridomas that produced anticytotoxic polysaccharide–specific mAbs were isolated and characterized as described previously (38) from a serotype A (ATCC 24064)–infected BALB/c mouse and a serotype A (NIAID 3711) GXM-TT conjugate (27)–immunized BALB/c mouse. These hybridomas were generated at the Albert Einstein College of Medicine Cancer Center Hybridoma Facility (Bronx, NY).

Apparent Affinity Constant (aka) Determination. The aka of each mAb for serotype A CNPS (CNPS-A) was determined by the method of Nieto et al. (39). The assay involved measuring the inhibition of mAb binding to CNPS-A–coated microtiter plates in the presence of soluble CNPS-A. 1.5 µg mAb was incubated 1.5 h at 37°C in the presence of decreasing concentrations of soluble CNPS-A in microtiter plates (25801; Corning Glass Works, Corning, NY) coated with 100 ng CNPS-A and blocked with 1% BSA and 0.5% horse serum. The assay was developed using alkaline phosphatase–labeled goat anti–mouse heavy chain–specific reagents (Fisher Biotech, Orangeburg, NY), followed by addition of alkaline phosphatase substrate (Sigma Chemical Co., St. Louis, MO). aka were calculated assuming a molecular weight of 1.4 × 106 for CNPS-A (40).

Southern Blot Hybridization. Productive and nonproductive rearrangements of the heavy and light chain genes were analyzed as described previously (18). For analysis of Ig heavy chain rearrangement patterns, hybridoma, NSO myeloma fusion partner, and BALB/c liver DNA were digested with the restriction enzyme EcoRI, and blots were probed with the 2-kg BamHI–EcoRI J3-J4 probe, J1 (41). For analysis of Ig light chain rearrangement patterns, hybridoma, NSO myeloma fusion partner, and BALB/c liver DNA were digested with the restriction enzyme HindIII, and blots were probed with the 2.7-kb HindIII–HindIII J1-5 probe (42).

mRNA Sequencing. Total cellular RNA was isolated by CsCl gradient sedimentation of hybridoma lysates prepared in a guanidinium solution (4, 23 M guanidine isothiocyanate: (Fluka BioChemika, Buchs, Switzerland), 0.017 M N-lauryl sarcosine, 0.025 M sodium citrate, pH 7.0, 0.015 M β-mercaptoethanol, 0.001% anti–foam A). Poly(A)+ mRNA was isolated using an oligo(dT) (Collaborative Research Incorporated, Bedford, MA) affinity column. The nucleotide sequence of hybridoma antibody mRNA was determined using a modification of the method of Gelieter et al. (43), and representative sequence data are available from EMBL/GenBank/DDBJ under accession numbers Lo5431 and Lo5432. The following oligonucleotides, synthesized in the DNA synthesis facility of the Cancer Center at our institution, were used as primers: TGGATGGTGGGAAAGTG (V4), GACCCCCAGAAATCGTTT (5' V4), TCTCGGAGGAGGCGGGAGGA (µg), GACCGAGGGAAGACATT (µg), GGGGGCGATTGAGATAC (γg), AAGTAGGCCTTTTGCAAGGCA (γg), GAGTGTCACTGGTTAGTATGGT (α), and TGTTCTTGGCATTTGTC (V7,183). Sequence searches and comparisons were performed using the Genetics Computer Group (GCG) Sequence Analysis Software (SAS) Package (44) and the sequence compilation of Kabat et al. (45). Theoretical replacement/silent (R/S) ratios were calculated using the Replacement/Substitution program written by D. Lustgarten and J. Mindell (Albert Einstein College of Medicine).

Protection Studies. Protection studies were performed as described in detail elsewhere (31). Briefly, ascites containing 600 µg mAbs 10FI0, 17E12, or 18B7, or 200 µl ascites from the non-Ig-producing fusion partner myeloma, NSO, were administered intraperitoneally to 10 female A/J mice in each group. Approximately 30 min later, 105 serotype D (ATCC 24067) C. neoformans was administered intraperitoneally. Serotype D cryptococci were used because we wanted to determine whether our mAbs generated against serotype A and reactive with serotypes A–D (38), would protect against both pathogenic serotypes. Results of each experiment were analyzed by a log–rank analysis program written by Dr. C. J. Chang (Albert Einstein College of Medicine) using the SAS statistical software package.

Results

mAbs. As previously reported (38), two independent sets of anticytotoxic antibody-producing hybridomas were isolated. Seven were derived from a serotype A C. neoformans–infected BALB/c mouse, and 22 were derived from a serotype A GXM-TT conjugate–immunized BALB/c mouse. These mAbs were of the IgM, IgG3, IgG1, and IgA heavy chain and κ light chain isotypes (Table 1), and based on competition experiments and reactivity with CNPS, all recognize the same antigenic determinant present on serotype A, B, C, and D CNPS (38). We have now characterized the molecular structure of each of these mAbs and determined their clonal origins and relative binding to CNPS.

Ig Gene Utilization. To determine the molecular structure and variable gene usage, the heavy and light chain Ig mRNA sequence of each mAb was determined for the heavy
Table 1. Hybridoma Clonal Families and mAb $V_u$ and $V_l$ Usage

| Group | B cell clone | Hybridoma | mAb isotype | aka | Gene usage |
|-------|-------------|-----------|-------------|-----|------------|
|       |             |           |             |     | $V_u$  | $J_u$  | $V_l$  | $J_l$  |
| A     | 1           | 8H3       | $\mu k$     |     | $V_u$7183 | $J_u$4 | $V_l$5.1 | $J_l$1 |
|       | 2           | 1E10      | $\mu k$     | 7.0 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 3B10      | $\gamma k$  | 3.0 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 3D1       | $\mu k$     | 21  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 4D4       | $\mu k$     | 1.5 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 5E9       | $\mu k$     | 13  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 7E5       | $\mu k$     | 19  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
| B     | 3           | 2D10      | $\mu k$     | 209 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 2H1         | $\gamma k$ | 2.5         |     | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 3H5         | $\gamma k$ | 13          |     | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 13G12       | $\alpha k$ | 1.6         |     | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 18G9        | $\alpha k$ | 1.3         |     | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 4a          | 4G9       | $\gamma k$  | 5.2 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 7G7       | $\mu k$     | 41  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 9F11      | $\gamma k$  | 1.8 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 12A1      | $\mu k$     | 38  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 12F4      | $\gamma k$  | 0.8 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 13F1      | $\mu k$     | 39  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 14E1      | $\gamma k$  | 1.3 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 15E8      | $\mu k$     | 6.1 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 16E4      | $\mu k$     | 0.8 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 18B7      | $\gamma k$  | 5.4 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 25G12     | $\alpha k$  | 1.6 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 4b          | 5E4       | $\mu k$     | 1.3 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 7D8       | $\alpha k$  | 0.5 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 10F10     | $\gamma k$  | 1.5 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       |             | 25E12     | $\gamma k$  | 1.7 | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 4c          | 9E11      | $\mu k$     | 12  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |
|       | 4d          | 17E12     | $\gamma k$  | 11  | $V_u$7183 | $J_u$2 | $V_l$5.1 | $J_l$1 |

* Too low to be measured.*

Groups A and B refer to hybridomas derived from a serotype A-infected mouse and a serotype A GXM-TT conjugate-immunized mouse, respectively.

The mAbs isolated from both the infected and GXM-TT conjugate-immunized mice define a highly restricted response with respect to Ig variable gene usage. 27 of the 29 mAbs isolated from both mice were very homologous to each other and almost certainly use the same germline $V_u$7183 gene element, have a seven-codon CDR3, and utilize $J_u$2, $V_l$5.1, and $J_l$1 (Table 1). A consensus $V_u$7183 sequence was derived based on the germline $V_u$7183:283 sequence (46) by incorporating into the $V_u$7183:283 sequence those base changes shared by all the mAbs from both the infected and GXM-TT conjugate-immunized mice. The consensus $V_u$7183 sequence is 94.9 and 95.6% homologous (44) to the germline $V_u$7183:283 (46) and $V_u$7183:10-19 (47) gene sequences, respectively, suggesting the anti-CNPS mAbs are encoded by an as yet unreported $V_u$7183 family member. When compared with the 29 mAb sequences, 18 mAbs had an A at the first base of codon 54 (Fig. 1), resulting in an asparagine residue. The two described germline $V_u$7183 (283 and 10-19) sequences (46, 47) each have a G at this position (Fig. 1) encoding an aspartic acid. Since
Table 2. $V_h$ and $V_l$ Ig Gene Rearrangement Patterns

| Group | Hybridoma* | H$^+$ | H$^-$ | L$^+$ | L$^-$ |
|-------|------------|-------|-------|-------|-------|
| A     | 8H3        | 2.4   | –     | 3.6   | –     |
|       | 1E10, 3B10, 4D4, 5E9 | 3.2 | 4.2 | 3.6 | – |
|       | 3D1        | 3.2   | –     | 3.6   | –     |
|       | 7E5        | 3.2   | 6.0   | 4.2   | 2.4   | 3.6   | – |
| B     | 2D10, 2H1, 3E5, 18G9, 13G12 | 3.2 | 2.8 | 3.6 | – |
|       | 4G9, 7G7, 9F11, 12A1, 12F4, 13F1 | 3.2 | – | 3.6 | – |
|       | 14E1, 15E8, 16E4, 18B7, 25G12 | 3.2 | – | 3.6 | 4.1 |
|       | 5E4, 7D8, 10F10, 25E12 | 3.2 | – | 3.6 | – |
|       | 9E11       | 1.8   | –     | 3.6   | –     |
|       | 17E12      | 3.2   | –     | 3.6   | 3.3   |

H$^+$ and H$^-$ refer to the productive and nonproductive rearrangement fragment sizes as determined with EcoRI-digested DNA probed with J$_{I1}$. L$^+$ and L$^-$ refer to the productive and nonproductive rearrangement fragment sizes as determined with HindIII-digested DNA probed with J$_{I1-5}$. *Hybridomas in groups A and B were isolated from the serotype A-infected and GXM-TT-immunized mice, respectively.

this base difference was not exhibited by all the mAbs and was not present in the known germline sequences, we did not include it in our consensus sequence. However, this $G \rightarrow A$ change may indeed be germline encoded or, alternatively, may be a somatic mutation that increases the binding of CNPS.

The $V_h$ CDR3 of the anti-CNPS mAbs can be organized into four different consensus nucleotide sequences (Fig. 1). Although CDR3 regions of individual mAbs deviate from the consensus CDR3 sequences, presumably due to somatic mutation, and are thus not identical, each encodes seven amino acids that include 5' arginine and aspartic acid residues followed by a highly conserved pattern of charge, polarity, and hydrophobicity. For example, the CDR3 sequence of the 1E10 group of mAbs from the infected mouse encodes 5' arginine, aspartic acid, glycine, tyrosine, phenylalanine, serine, and histidine 3'. The CDR3 of the 4G9 group of mAbs from the conjugate-immunized mouse encodes 5' arginine, aspartic acid, glycine, threonine, serine, glycine, and threonine 3' (Fig. 1). Unusual reading frames, inversions, deletions, and combinations of reported germline D sequences (45) were examined, but it was not possible to identify a known D segment in our mAbs. Therefore we do not know whether a germline D element participated in the formation of the $V_h$ CDR3 or whether this region of our antibodies is at least partially due to N sequences introduced enzymatically during VDJ rearrangement (48, 49). The light chains of all the mAbs use the same $V_l$ and $J_l$ gene elements and have the same $V_l$-$J_l$ junctions (data not shown), suggesting that these specific light chain sequences are important in formation of a binding site capable of interacting with CNPS.

2 of the 29 mAbs, 8H3 from the infected mouse and 17E12 from the GXM-TT conjugate-immunized mouse, utilize similar Ig gene elements as the other mAbs but have structural differences within these elements. mAb 8H3 utilizes the same D and $V_h$ sequences as the other 27 mAbs, but its $V_h$7183 sequence has a two-codon deletion at positions 55 and 56 relative to the $V_h$7183 consensus sequence (Fig. 1). It is conceivable that the 8H3 $V_h$ sequence represents another member of the $V_h$7183 family or, alternatively, the missing codons are merely due to a deletional somatic mutation. In addition, 8H3 uses $J_l$4 (Table 1) with a 5' two-codon deletion, resulting in a $J_l$ region that encodes the same number of amino acid residues and displays the same

Figure 1. $V_h$ nucleotide sequences of the anti-CNPS mAbs. The mAbs in the 8H3 and 1E10 groups were isolated from the serotype A-infected mouse. The mAbs in the 2D10 and 4G9 groups were isolated from the serotype A GXM-TT conjugate-immunized mouse. Sequences from clonally related hybridomas are grouped, followed by a space. $V_h$ sequences are compared to the consensus $V_h$7183 sequence. The N/D region sequences are compared with consensus sequences determined from the mAbs within each clonally related group. The $J_h$ sequences are compared with $J_h$2 or $J_h$4. Spaces indicate that the sequence is uncertain or has not been determined; dashes indicate identity; (DEL) deletion of a codon; asterisks indicate uncertainty in a base due to compression; capital letters indicate nucleotide changes resulting in amino acid replacements; silent nucleotide changes are indicated by lower-case letters. Framework (FR) and CDR (45) are indicated above the consensus $V_h$, D, and germline $J_h$2 and $J_h$4 sequences. The ACA codon at the 3' end of the hybridoma 3E5 $J_h$2 sequence is reported by Kabat et al. (45) to be the first 5' codon of the IgG3 heavy chain constant region. However, we (18) and others (Joan L. Press, personal communication) have discovered an intervening GCT codon 3' of $J_h$ and 5' of the ACA codon that is not encoded by any $J_h$ sequence or by the reported IgG3 constant heavy chain gene. $V_h$7183:283 (46) and $V_h$7183:10-19 (47) are germline BALB/c sequences; $V_h$62 is from BALB/c hybridoma mAb 62 (84); and the $J_h$2 and $J_h$4 germline sequences were obtained from Kabat et al. (45).
junctinal amino acid as that encoded by the J_{2} region used by all the other mAbs (Fig. 1). mAb 17E12 utilizes the same Ig gene elements (the same V_{\gamma}7183 consensus, J_{\alpha}, V_{\delta}5.1, and V_{\gamma}1) and the sequence of its CDR3 is very similar to the other mAbs, except for a one-codon deletion at residue 102 (Fig. 1).

**Clonal Origin of Hybridomas.** The finding that all the anticytotoxic hybridomas isolated (except 8H3, which uses J_{\gamma}4 instead of J_{\alpha}2) utilize the same combination of heavy and light chain Ig gene elements (Table 1) suggests the responses that occurred in both the infected and conjugate-immunized mice were oligoclonal. The clonal origin of each response was studied by examining the heavy and light chain Ig gene rearrangement patterns of each hybridoma by Southern blot hybridization (Table 2). The J_{\gamma}3-J_{\gamma}4 probe (J_{\gamma}11) hybridizes to EcoRI germline BALB/c liver DNA restriction fragments of 6.4 and 5.4 kb, and a NSO myeloma restriction fragment of 6.6 kb. The light chain J_{\delta}1-5 probe hybridizes to HindIII germline BALB/c liver and NSO myeloma DNA restriction fragments of 2.4 and 6.4 kb, respectively. Table 2 summarizes the sizes of the productive and nonproductive J_{\gamma}11 heavy and J_{\gamma}1-5 light chain hybridizing restriction fragments, but does not include germline (i.e., unrearranged) and myeloma fragments. The productive rearrangement of the V_{\gamma}7183 consensus and J_{\alpha}2 sequences used by all the hybridomas (except 8H3) was assigned to the 3.2-kb band, which is the only hybridoma-specific restriction fragment common to the heavy chain J_{\gamma}11 hybridization patterns of all hybridomas, except 9E11 and 8H3 (Table 2). The 9E11 hybridization pattern lacked the 3.2-kb band, presumably due to a change in a restriction site resulting from somatic mutation. Therefore, the productive 9E11 V_{\gamma}7183-J_{\alpha}2 rearrangement was assigned to the sole hybridoma-specific 1.8-kb band. The productive rearrangement of the V_{\gamma}7183 consensus and J_{\gamma}4 sequences used by hybridoma 8H3 was assigned to the single 2.4-kb hybridoma-specific J_{\gamma}11-hybridizing band. The productive rearrangement of the V_{\delta}5.1 and J_{\delta}1 light chain sequences used by all the anticytotoxic hybridomas was assigned to the 3.6-kb band present in each J_{\delta}1-5-hybridizing light chain rearrangement pattern. The remaining heavy and light chain hybridoma-specific rearrangement pattern bands were assumed to be due to nonproductive Ig gene rearrangements (Table 2).

Patterns of heavy chain rearrangement in conjunction with CDR3 sequences were used to determine the clonal relatedness of the hybridomas isolated from each response. Somatic mutations present in several members of a clone are more likely to represent a single inherited mutational event rather than multiple independent identical events, and were thus used along with patterns of light chain rearrangement to confirm clonal assignment and arrange hybridomas from each clone into specific genealogical sublineages (Table 1) (50–53). The hybridomas isolated from the infected mouse exhibit four distinct patterns of heavy chain rearrangement (Table 2), suggesting four progenitor B cells generated the seven B cells isolated as hybridomas from this response. Since its Ig heavy chain uses J_{\gamma}4 instead of J_{\gamma}2 (Table 1), hybridoma 8H3 is clearly the product of a separate B cell ancestor, designated clone 1. Since hybridomas 1E10, 3B10, 4D4, and 5E9 share the same pattern of heavy and light chain productive and nonproductive rearrangements (Table 2), have very similar CDR3 sequences and junctions (Fig. 1), and V_{\gamma}1-J_{\gamma}4 junctions, they must have been derived from a second common ancestral B cell (clone 2 in Table 1) (52). Although hybridomas 3D1 and 7E5 each exhibit different heavy chain rearrangements and could have been derived from two separate B cell precursors, nucleotide sequence homology, including CDR3 and its junctions (Fig. 1), strongly suggests 3D1 and 7E5 were also derived from clone 2 (52). It is important to note that while nonproductive rearrangements are very useful in establishing clonal relationships, they can easily be lost as hybridomas reduce their chromosome load (54). We cannot explain the multiple fragments in the 7E5 heavy chain rearrangement pattern (Table 2), though it is conceivable 7E5 arose from a triple fusion. Thus, the hybridomas isolated from the infected mouse were probably derived from two, but not more than four, separate B cell precursors, and clone 2 dominated the response.

Three separate heavy chain rearrangement patterns were exhibited by the hybridomas isolated from the GXM-TT conjugate-immunized mouse (Table 2). However, besides the 17E12 six-amino acid D, only two distinct seven-amino acid CDR3 sequences are present in mAbs from the conjugate-immunized mouse (Fig. 1), suggesting these hybridomas are derived from only two different B cell precursors. Based upon common productive and nonproductive heavy chain rearrangement patterns and CDR3 sequence homology, hybridomas 2D10, 2H1, 3E5, 18G9, and 13G12 were derived from a common precursor B cell (clone 3 in Table 1). Similarly, hybridomas 4G9, 7G7, 9F11, 12A1, 12F4, 13F1, 14E1, 15E8, 16E4, 18B7, and 25G12 were derived from a second common precursor B cell (clone 4a). 5E4, 7D8, 10F10, and 25E12 also have the same CDR3 sequence as members of clone 4a, but have an additional, presumably nonproductive, light chain rearrangement pattern (Table 2). As noted above, lack of this nonproductive rearrangement by some members of clone 4 may be due to chromosome loss. We have provisionally assigned hybridomas 5E4, 7D8, 10F10, and 25E12 to a separate branch of clone 4, designated 4b (Table 1), but they may represent a separate clone due to their unique light chain rearrangement pattern and somatic mutational differences (Fig. 1). Although hybridoma 9E11 displays a different heavy chain rearrangement pattern, presumably due to somatic mutation, its CDR3 sequence is the same as that of hybridoma 12F4 and 25E12 (Fig. 1), and its light chain rearrangement is the same as those of clone 4a (Table 2), suggesting but not proving 9E11 was also derived from clone 4. Although hybridoma 17E12 has the same heavy chain rearrangement pattern as clone 4a and 4b members, it does not share the same light chain pattern (Table 2). Moreover 17E12 has a six-, not seven-, amino acid D segment (Fig. 1). However, alignment of the six amino acids within the 17E12 CDR3 relative to others in clones 4a and 4b (Fig. 1) indicates that with the exception of the one-codon deletion, the sequence is identical to that of other mAbs in these clones, including mAbs 5E4 and 7G7. Thus, it is not possible to ascertain whether 17E12 is a member of clone 4 that underwent a deletion and a separate light chain rearrangement, or was the product of a separate B cell
Table 3. R/S Ratios and Incidence of Somatic Mutation in the Vα of Selected Clones

| B cell clone | R/S ratios | Incidence of somatic mutation* |
|--------------|------------|-------------------------------|
|              | CD2 codons | FRs  | CDR1 | 50-66 | 50-58 | CDR3 | FRs  | CDR1 | 50-66 | 50-58 | CDR3 |
| Theoretical1 |            | 2.76 | 5.56 | 3.34  | 3.24  | -     | 0.014 | 0.016 | 0.052 | 0.08  | 0.025 |
| 2            |            | 16/6 | 2/0  | 16/0  | 13/0  | 4/1   | 0.0055| 0.019 | 0.047 | 0.067 | 0.012 |
| 3            |            | 5/2  | 2/0  | 10/2  | 8/1   | 2/0   | 0.012 | 0.019 | 0.026 | 0.044 | 0.026 |
| 4a,b         |            | 29/17| 4/2  | 18/2  | 17/1  | 11/2  | 0.012 | 0.019 | 0.026 | 0.044 | 0.026 |

* Incidence of somatic mutation is the ratio of the total number of unique somatic mutations to the total number of bases within a particular region of all the members of a clone.

1 The theoretical R/S ratios, determined using the Replacement/Substitution Program, represent the relative number of replacement-to-silent mutations that would be expected if somatic mutation of each were entirely random.

2 The theoretical R/S CD3 ratios of the mAbs in clones 2, 3, and 4a,b are 4.0, 4.0, and 4.75, respectively.

precursor, designated clone 4d. Thus, although we may have recovered hybridomas from as many as five different B cell precursors, the conjugate response was dominated by two or possibly three B cell clones.

Somatic Mutations. Somatic mutations relative to consensus Vα and CD3 and germline Jα, Vα, and Jα Ig sequences were observed for all the anticytostoccal mAbs from both the infected and GXM-TT conjugate-immunized mouse. Most of the light chains had between one and five somatic mutations randomly distributed throughout the framework and CDRs (data not shown). There were more mutations in the heavy chain (Fig. 1 and Table 3), as has also been observed in other responses (55). Table 3 summarizes the number of unique replacement (R) and silent (S) mutations present in the heavy chain of the mAbs in clones 2-4. Mutations present in more than one member of a clone were considered to be due to an inherited event and were counted only once. The ratio of R/S mutations in each B cell clone can be compared to theoretical values of each variable region segment calculated for that particular segment assuming somatic mutation is a random event. The R/S ratios of Vα CD2 (codons 50-66) for clones 2, 3, 4a, and 4b are considerably higher than the theoretical R/S ratio for this region (Table 3). Moreover, the bulk of these contributory R mutations are clustered at the 5' end of CD2 between codons 50 and 58 (Fig. 1 and Table 3). The high R/S ratios and localization of these replacement mutations within a discrete region of CD2 strongly suggests antigen selection was involved and that these somatic mutations are not the result of random events. The incidence of somatic mutation is also higher in CDR2, especially between codons 50 and 58, than in CDRs 1 and 3 and the frameworks. The incidence of somatic mutation within each region of the mAbs in each clone also indicates that the relative occurrence of somatic mutation in each mAb is approximately the same in each clone (Table 3).

mAb Apparent Affinity. The aka's were compared by determining the amounts of soluble CNPS-A required to inhibit the binding of the antibody to immobilized CNPS-A (39), as described in Materials and Methods. The aka's of the IgG mAbs were within a 15-fold range. The aka's of the IgA antibodies exhibited similar aka's, and although IgA molecules are polymeric, their aka's were within the range of aka's exhibited by the IgG mAbs, suggesting the real affinities of the IgA mAbs may be lower than the IgG mAbs. Even within a single clone (Table 1, clone 4a), the IgM mAbs from the response to GXM-TT conjugate immunization had a wider range of relative binding than IgM mAbs isolated from the response to cryptococcal immunization, suggesting affinity maturation occurred in response to the GXM-TT conjugate (see below).

Protection Experiments. We have previously shown that the IgG1 mAb 2H1 from clone 3 effectively prolonged survival of mice lethally infected with C. neoformans (31). This prompted us to determine whether mAbs from other B cell clones stimulated by GXM-TT conjugate immunization were also protective. The IgG1 mAbs 18B7, 10F10, and 17E12 are derived from clones 4a, 4b, and 4d, respectively, and have somewhat different aka's (Table 1). Fig. 2 shows survival data for untreated mice (NSO) and mice treated with 2H1, 18B7, 10F10, and 17E12. The survival curves for treated mice are significantly different from the untreated control. The survival of mice treated with 2H1 is significantly prolonged compared to the untreated control, indicating that this mAb is protective against C. neoformans infection. The survival of mice treated with 18B7, 10F10, and 17E12 is also significantly prolonged compared to the untreated control, indicating that these mAbs are also protective against C. neoformans infection.
of A/J mice given 600 µg mAb 10F10, 17E12, or 18B7 intraperitoneally before intraperitoneal challenge with 10⁸ serotype D (ATCC 24067) C. neoformans. All three mAbs provided passive protection as evidenced by their ability to prolong survival. Mice given mAbs 10F10, 17E12, or 18B7 lived an average of 146 ± 33, 80 ± 13, or 100 ± 31 d, respectively, while control mice lived only 11 ± 0.3 d. However, the results are best reflected in Fig. 2 because these calculated survival values are biased due to the presence of some very long-term survivors in the experimental groups. The ability to prolong survival did not correlate with mAb aka since 17E12 and 10F10, which differ by 10-fold in aka, each give similar levels of protection, and 18B7 with an intermediate aka was the least protective (Table 1 and Fig. 2). However, in conjunction with our previous studies (31), this result does indicate that each B cell progenitor stimulated by the GXM-TT conjugate gave rise to protective antibodies.

Discussion

We have examined the molecular origins of the BALB/c murine humoral response to serotype A cryptococcal polysaccharide in infected and GXM-TT conjugate-immunized mice. On the basis of the hybridomas isolated, only a few progenitor B cells within each spleen proliferated to produce the B cell progeny responsible for each anticryptococcal response. The actual numbers of hybridomas isolated from each response can be used to obtain a rough estimate of the number of B cells activated in vivo, for it has been estimated that one hybridoma is isolated for every 10³ to 10⁴ activated B cells (56). Clonal analysis of the hybridomas from the infected mouse suggests that there was one dominant clone represented by five to six hybridomas, whereas the two major clones, 3, and 4a, isolated from the GXM-TT-immunized mouse, were represented by 5 and 11 members, respectively. Based on the number of hybridomas isolated, ~7,000–70,000 B cells were activated in the spleen of the infected mouse, whereas ~22,000–220,000 B cells were activated in the spleen of the GXM-TT conjugate–immunized mouse. Comparison of these estimates strongly suggests many more activated B cells were present in the spleen after conjugate immunization, consistent with the fact that GXM-TT conjugate–immunized mice had higher anticryptococcal serum titers than infected mice (38). This indicates the TD activity of the GXM-TT conjugate induced greater clonal proliferation relative to that induced by CNPS during cryptococcal infection.

Restriction with regard to antibody binding site structure was observed at several levels, including utilization of the same Ig heavy and light chain gene elements (the same germline Vh,7183 family member, Jh,2/Jh,4, Vλ,5.1, and Jλ,1), joining of these particular genes at the same nucleotides, and a CDR3 with a highly conserved size and pattern of charge and polarity. The need for an antibody molecule with a conserved spatial arrangement of structural elements was emphasized by the finding that mAb 8H3 utilized a Jλ,4 gene that had a deletion of two 5' codons, resulting in a Jλ, region that encoded the same number of amino acids as that encoded by the Jλ,2 gene utilized by all the other mAbs.

Although compared with antiprotein responses antipolysaccharide responses are typically characterized as being "restricted" with regard both to isotype and clonotype (57–64), restriction is a relative term. For example, although mAbs specific for α-(1→6)-dextran have been shown to use a limited subset of Vh genes, there is considerable junctional diversity and variation in the combinations of Vh and Vl genes utilized (60, 65, 66). Likewise, the response to group A streptococcal polysaccharide has been shown to be characterized by a heterogeneous population of antibodies (59). Similarly, the TI response to NP-Ficoll is characterized by utilization of a variety of Vh, D, and Jλ genes and their combinations (67). In contrast, the response to bacterial levan is somewhat more restricted, as indicated by a recently characterized set of mAbs that utilize gene elements from only three or four Vh families (57). The response to 3-fucosyllactosamine is even more restricted and characterized by mAbs composed of Vh,441 and Vl,24B (61, 62). However, with its preferential Vh and Vl gene usage, lack of junctional diversity, and conserved CDR3 sequences, the anticryptococcal response appears to be among the most highly restricted antibody responses described to date (18). The finding that all the anti-CNPS mAbs (except 8H3) utilize the same Vh region elements suggests very few antigen binding sites are available that will suffice for recognition of cryptococcal polysaccharide and/or that the response was directed by structural features of the antigen. In vivo, a single dominant immunogenic epitope of cryptococcal polysaccharide may be recognized. This epitope may also be structurally simple, however, structural simplicity is not sufficient to mediate restriction of Ig gene usage for highly defined epitopes that can be recognized by a diverse set of Vh and Vl regions (68). In fact, even though polysaccharides are composed of fewer types of chemical subunits than proteins, they have greater conformational and rotational freedom than proteins and can thus assume a greater multiplicity of structures (69, 70). Alternatively, only a subset of B cells, defined by their Ig gene usage, may be capable of responding to cryptococcal polysaccharide. Indeed, CNPS may mimic a self-antigen, and the responder B cells may be those that either do not produce a self-reactive antibody or can easily escape clonal deletion or anergy.

Somatic mutations were observed within the Ig Vh and Vl sequences of all the anti-CNPS hybridomas isolated from both infected and conjugate-immunized mice. In particular, Vh CDR2 exhibited a relatively high rate of somatic mutation. This region could be a somatic mutational "hot spot" (71, 72). Alternatively, a selective advantage may be conferred to B cells expressing surface Iggs with such mutations since CDRs encode amino acids that contact the antigen (73) and could confer increased affinity and/or changes in epitope specificity (74–77). Indeed, although the Ig gene elements utilized by the anti-CNPS mAbs were the same, differences in both mAb's apparent affinity and fine specificity were observed. The IgM mAbs isolated from the infected mouse all exhibited akas between 1.5 × 10⁹ and 2 × 10¹⁰ M, whereas
the IgM mAbs isolated from the GXM-TT conjugate–immunized mouse exhibited a broader range of akas even within a single clone (Table 1). Selection of high affinity clones in response to conjugate immunization is likely since only a small amount (5 μg) of the antigen was present (38). Conversely, during infection, affinity maturation may not occur simply because there are very large amounts of antigen in circulation, and thus a high affinity Ig receptor may not provide a selective advantage.

The incidence of base changes and the relatively high ratio of replacement mutations in the heavy chain CDR2 suggest the response to CNPS is antigen driven and antigen selected. Since some of the mAbs within each of the clones have higher akas than others of the same isotype (Table 1), somatic mutation must be responsible for the differences in affinity. However, accumulation of somatic mutations did not necessarily lead to higher affinity mAbs, i.e., affinity maturation. For example, one of the highest binding (4.1 × 10^10 M) mAbs, 7G7, from clone 4a, contains relatively few somatic mutations and replacement substitutions (V\_\text{H}: 50, thr→ileu, 84, ser→thr, 95, tyr→phe; V\_\text{L}: 90, val→ileu, 95, glu→leu). 7G7 also lacks the asparagine and aspartic acid substitutions at codons 54 and 56, respectively, which are present in most of the mAbs, including mAbs with high akas such as 2D10. Using somatic mutations present in the heavy and light chain sequences, we organized the members of clone 4a into a possible genealogy (Fig. 3). We have tried to compare other members of the 4a genealogy that are of the same isotype but differ with respect to aka. The IgM mAbs 15E8 and 12A1 differ by sixfold in aka (Table 1) and by 14 heavy and light chain amino acid substitutions, five of which are in CDRs (Fig. 1). Similarly, 16E4 and 13F1 differ by 40-fold in aka and by 11 amino acid substitutions, seven of which are in CDRs. In addition, relative to the monomeric IgG1 mAbs, the dimeric IgA mAbs of clones 3 and 4a have unexpectedly low akas (Table 1). Since a single amino acid substitution can result in a 10-fold increase in affinity or complete loss of antigen binding (77, 78), it is difficult to identify specific amino acid substitutions responsible for differences in antigen binding in the absence of a three-dimensional antigen binding site model. These hybridomas almost certainly represent a "snapshot" of a single point during the ongoing process of the immune response in which Igs with a spectrum of affinities are produced. Thus, using hybridomas, it may be difficult to demonstrate that accumulated mutations lead to an increase in affinity. Indeed, as long as a particular threshold affinity is maintained, it may not matter in the response to CNPS whether very high akas are attained, since lower affinity antibodies may be sufficient to trigger proliferation in response to this polymeric antigen. Apparent akas may also not accurately reflect the efficacy of antigen-antibody interactions in triggering B cell proliferation (79).

Figure 3. Schematic representation of one possible genealogy for the members of clone 4a. The progenitor B cell is represented by the large circle. Individual hybridomas are indicated by smaller circles designated with the respective mAb name, isotype, and apparent affinity (× 10^9/M).

> B > D > C. However, the fine specificity pattern of 13F1 is A > B > C > D (38). Since the gene utilization and combinatorial joining of these elements is identical among the members of clone 4a, somatic mutation must be responsible for the difference in fine specificity, supporting a similar observation by Clarke et al. (80). A unique three-base change at V\_\text{H} residue 38, which results in an arginine to threonine substitution, may contribute to the change in fine specificity exhibited by mAb 13F1.

Molecular analysis of the antibody response to infection and GXM-TT immunization revealed that both responses are very similar. mAbs from both responses have the same epitope specificity (38), use the same V\_\text{H} and V\_\text{L} genes, and have somatic mutations. The most striking difference between the two sets of hybridomas is the isotype distribution. IgM mAbs dominated the response to infection, and IgG mAbs dominated the response to GXM-TT conjugate immunization. The finding that specific mAbs isolated from both responses utilize a highly restricted repertoire of Ig gene elements suggests both infection and conjugate immunization stimulate the same discrete subpopulation of B cells, and moreover indicates preservation of biologically relevant epitopes within the GXM-TT conjugate. Since the response was both oligoclonal and highly restricted, it is likely that only a few progenitor B cells in each mouse exhibited the particular V\_\text{H}DJ\_\text{H} combination needed to respond to the cryptococcal antigens presented in association with the appropriate light chain. Since a response was elicited by all mice immunized with the GXM-TT conjugate (38), each mouse must have B cells with the required V\_\text{H}DJ\_\text{H} rearrangement capable of associating with the necessary V\_\text{L} gene combination. This strongly
suggestions that the absence of an antibody response observed for the majority of infected mice (18, 38) is not due to lack of the necessary B cell but rather to immune paralysis induced by the large amounts of CNPS present (81). We have previously proposed that the ~5% of mice that do respond to cryptococcal infection are those that had prior exposure to a crossreactive TD antigen and that infection stimulated residual memory B cells (18, 38). The finding that the incidence and nature of somatic mutations in CDR2 of the antibodies from the infected mouse were comparable to those isolated from the GXM-TT conjugate-immunized mouse (Fig. 1 and Table 3) is indeed consistent with the view that infection stimulated a secondary response (18).

The results of the study presented here are of fundamental importance not only with regard to understanding the physiology of the B cell populations involved in the humoral response against C. neoformans, but also with respect to vaccine design and passive mAb therapy. The GXM-TT conjugate (or a similar derivative) is a potential vaccine for individuals at risk for cryptococcosis (27). Since individuals with serum anticytococcal antibodies have a more favorable prognosis (25), the finding that GXM-TT conjugate immunization and cryptococcal infection stimulate the same subpopulation of B cells is important for it implies GXM-TT vaccination will elicit the same type of antibodies occasionally present in infected individuals. Moreover, each B cell clone stimulated by the GXM-TT conjugate produced protective antibodies, as demonstrated by our previous finding that IgM, IgG1, and IgA mAbs from clone 3 (31), as well as the IgG1 mAbs 18B7, 10F10, and 17E12 isolated from clones 4a, 4b, and 4d, respectively, prolong survival of lethally infected mice. This is an important observation, for not all mAbs prolong survival (31, 36). The mAbs described here are potentially useful reagents for cryptococcal polysaccharide detection (82), structural analysis of capsular epitopes (12, 83), and passive immunotherapy of cryptococcosis (30, 31, 35, 36).

We thank Terri Kelly, Yoon Young Jhang, Gerardo Gomez, and Susan Buhl for expert technical assistance in various aspects of this work and Nancy Drenzyk for help in preparing this manuscript. We also thank Dr. Chee Jen Chang for his invaluable assistance in the statistical analysis of the protection data.

This work was supported by National Institutes of Health grants CA-39839-07, CA-13330-20, and AI-10702-20. J. Mukherjee is supported by NIH training grant 2T32C809173-16. M. D. Scharff is supported in part by the Harry Eagle Chair provided by the Women's Division of the Albert Einstein College of Medicine. A. Casadavall was supported by a Pfizer Postdoctoral Fellowship.

The data in this paper are from a thesis submitted by J. Mukherjee in partial fulfillment of the requirements of the Degree of Doctor of Philosophy in the Sue Golding Graduate Division of Medical Science, Albert Einstein College of Medicine, Yeshiva University.

Address correspondence to Matthew D. Scharff, Albert Einstein College of Medicine, Chanin Building, Room 330, 1300 Morris Park Avenue, Bronx, NY 10461.

Received for publication 27 August 1992 and in revised form 28 December 1992.

References

1. Diamond, R.D. 1985. Cryptococcus neoformans. In Principles and Practice of Infectious Disease. Mandell, G.L., R.G. Gordon, Jr., and J.E. Bennett, editors. John Wiley & Sons, Inc., New York. 1460-1468.
2. Zuger, A., E. Louie, R.S. Holtzman, M.S. Simberkoff, and J.J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Arch. Intern. Med. 104:240.
3. Kozel, T.R., and J.R. Cazin, Jr. 1971. Nonencapsulated variant of Cryptococcus neoformans. I. Virulence studies and characterization of soluble polysaccharide. Infect. Immun. 3:287.
4. Bennett, J.E., H.F. Hasenclever, and B.S. Tynes. 1964. Detection of cryptococcal polysaccharide in serum and spinal fluid. Value in diagnosis and prognosis. Trans. Ass. Am. Physician. 77:34.
5. Bloomfield, W., M.A. Gordon, and D.F. Elmendorff, Jr. 1963. Detection of Cryptococcus neoformans antigen in body fluids by latex agglutination. Proc. Soc. Exp. Biol. Med. 114:64.
6. Wilson, D.E., J.E. Bennett, and J.W. Bailey. 1968. Serologic grouping of Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA. 127:820.
7. Ikeda, R., T. Shinoda, T. Fukushima, and L. Kaufman. 1982. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J. Clin. Microbiol. 16:22.
8. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaudemans. 1978. On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C. Immunochemistry. 15:673.
9. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaudemans. 1979. On the structure of the capsular polysaccharide form Cryptococcus neoformans serotype C-II. Mol. Immunol. 16:531.
10. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaudemans. 1980. Structural studies on the major, capsular polysaccharide from Cryptococcus neoformans serotype B. Carbohydr. Res. 82:103.
11. Bhattacharjee, A.K., K.J. Kwon-Chung, and C.P.J. Glaudemans. 1981. Capsular polysaccharides from a parent strain and from a possible mutant strain of Cryptococcus neoformans sero-
24. Diamond, K.D. 1974. Antibody-dependent killing of
22. Kozel, T.R., and J.L. Follette. 1981. Opsonization of encapsu-
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
26. Dromer, F., P. Aucuoturier, J.-P. Clauvel, G. Saimot, and P.
25. Diamond, R.D., and J.E. Bennett. 1974. Prognostic factors
28. Eckert, T.F., and T.K. Kozel. 1987. Production and character-
19. Miller, M.F., T.G. Mitchell, W.J. Storkus, and J.K. Dawson.
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, R. Cherniak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
19. Miller, M.F., T.G. Mitchell, W.J. Storkus, and J.R. Dawson.
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
21. Levitz, S.M., and D.J. DiBenedetto. 1988. Differential stimu-
10. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
20. Nabavi, N., and J.W. Murphy. 1986. Antibody-dependent nat-
29. Goren, M.B., and G.M. Middlebrook. 1967. Protein conjugates
18. Casadevall, A., and M.D. Scharff. 1991. The mouse antibody
17. Dromer, F., P. Yeni, and J. Charreire. 1988. Genetic control
15. Baker, P.J., D.F. Amsbaugh, P.W. Stashak, G. Caldes, and B.
14. Merrifield, E.H., and A.M. Stephen. 1980. Structural investi-
16. Cauley, L.K., and J.W. Murphy. 1979. Response of congeni-
13. Cherniak, K., E. Reiss, M.E. Slodki, L.L.D. Plattner, and S.O.
12. Todaro-Luck, F., E. Reiss, K. Chemiak, and L. Kaufman. 1989.
11. Cherniak, R., E. Reiss, M.E. Slodki, R.D. Plattner, and S.O.
Increased frequency of N-region insertion in a murine pre-B-cell line infected with a terminal deoxynucleotidyl transferase expression vector. *Mol. Cell. Biol.* 7:3237.

49. Desderio, S., G.D. Yancopoulos, M. Paskind, E. Thomas, M.A. Boss, N.R. Landau, F.W. Alt, and D. Baltimore. 1984. Insertion of N-regions into heavy-chain genes is correlated with expression of terminal deoxynucleotidyl transferase in B cells. *Nature (Lond.)* 311:752.

50. Rudikoff, S., M. Pawiita, J. Pumphrey, and M. Heller. 1984. Somatic diversification of immunoglobulins. *Proc. Natl. Acad. Sci. USA.* 81:2162.

51. Manser, T. 1990. Regulation, timing, and mechanism of antibody V gene somatic hypermutation: lessons from the arsate system. In *Somatic Hypermutation in V-Regions.* Steele, E.J., editor. CRC Press, Inc., Boca Raton. 41–54.

52. Litwin, S., and M. Schlomchik. 1990. A test for clonal relatedness in a set of lymphocytes. *J. Exp. Med.* 171:293.

53. Schlomchik, M., M. Mascalii, H. Shan, M.Z. Radic, D. Pisetsky, A. Marshak-Rothstein, and M. Weigert. 1990. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. *J. Exp. Med.* 171:265.

54. Galfré, G., and C. Milstein. 1981. Preparation of monoclonal antibodies: Strategies and procedures. *Methods Enzymol.* 73:3.

55. Clarke, S., R. Rickert, M.K. Wloch, L. Staudt, W. Gerhard, and M. Weigert. 1990. The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. Nonrandom silent mutation and unequal numbers of V, and V, mutations. *J. Immunol.* 145:2286.

56. Sahilitzky, F., G. Wildner, and K. Rajewsky. 1985. Somatic mutation and clonal expansion of B cells in antigen-driven immune response. *EMBO (Eur. Mol. Biol. Organ.) J.* 4:345.

57. Boswell, C.M., D.C. Irwin, J. Goodnight, and K.E. Stein. 1992. Strain-dependent restricted V, and V, usage by antibacterial levan monoclonal antibodies. *J. Immunol.* 148:3864.

58. Perlmuter, R.M., D. Hamburg, D.E. Briles, R.A. Nicolotti, and J.M. Dave. 1978. Subclass restriction of murine anti-carbohydrate antibodies. *J. Immunol.* 121:566.

59. Nahm, M.H., B.L. Clevinger, and J.M. Davie. 1982. Monoclonal antibodies to streptococcal group A carbohydrate. I. A dominant idiotypic determinant is located on V,1. *J. Immunol.* 129:1513.

60. Sidker, S.K., P.N. Akolkar, P.M. Kaladas, S.I. Morrison, and E.A. Kabat. 1985. Sequences of variable regions of hybridoma antibodies to α(1→6)-dextran in BALB/c and C57BL/6 mice. *J. Immunol.* 135:4215.

61. Kimura, H., R. Cook, K. Meek, M. Umeda, E. Ball, J.D. Capra, and D.M. Marcus. 1988. Sequences of the V, and V, regions of murine monoclonal antibodies against 3-fucosyllactosamine. *J. Immunol.* 140:1212.

62. Kimura, H., E.S. Buescher, E.D. Ball, and D.M. Marcus. 1989. Restricted usage of V, and V, genes by murine monoclonal antibodies against 3-fucosyllactosamine. *Eur. J. Immunol.* 19:1741.

63. Slack, J., G.P. Der-Balian, M. Nahm, and J.M. Davie. 1980. Subclass restriction of murine antibodies. I. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. *J. Exp. Med.* 151:853.

64. Mosier, D.E., and B Subbarao. 1982. Thymus-independent antigens: Complexity of B-lymphocyte activation revealed. *Immunol. Today.* 3:217.

65. Borden, P., and E.A. Kabat. 1987. Nucleotide sequence of the cDNAs encoding the variable region heavy and light chains of a myeloma protein specific for the terminal nonreducing end of α(1→6)-dextran. *Proc. Natl. Acad. Sci. USA.* 84:2440.

66. Akolkar, P.N., S.K. Sikder, S.B. Bhattacharya, J. Liao, F. Gruezo, S.L. Morrison, and E.A. Kabat. 1987. Different V, and V, germ-line genes are used to produce similar combining sites with specificity for α(1→6)-dextran. *J. Immunol.* 138:4472.

67. Maizels, N., and A. Bothwell. 1985. The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. *Cell.* 43:715.

68. Andria, M.L., S. Levy, and E. Benjamini. 1990. Diverse V, and V, genes are used to produce antibodies against a defined protein epitope. *J. Immunol.* 144:2614.

69. Kabat, E.A. 1968. Antigens. In *Structural Concepts in Immunology and Immunochemistry.* Kabat, E.A., editor. Holt, Rinehart, & Winston, Orlando, FL. 16–41.

70. Sutherland, I.W. 1977. Immunochernical aspects of polysaccharide antigens. In *Immunchemistry: An Advanced Textbook.* Steward, G., editor. John Wiley & Sons, Inc., New York. 399–443.

71. Berek, C., and C. Milstein. 1987. Mutation drift and repertoire shift in the maturation of the immune response. *Immunol. Rev.* 96:23.

72. French, D.L., R. Laskow, and M.D. Scharff. 1989. The role of somatic hypermutation in the generation of antibody diversity. *Science (Wash. DC).* 244:1152.

73. Padlan, E.A., D.D. Davies, S. Rudikoff, and M. Potter. 1981. Structural basis for the specificity of phosphocholine-binding immunogolubins. *Immunchemistry.* 13:945.

74. Fish, S., M. Fleming, J. Sharon, and T. Manser. 1991. Different epitope structures select distinct mutant forms of an antibody variable region for expression during the immune response. *J. Exp. Med.* 173:655.

75. Cook, W.D., S. Rudikoff, A.M. Guisti, and M.D. Scharff. 1982. Somatic mutation in a cultured mouse myeloma cell affects antigen binding. *Proc. Natl. Acad. Sci. USA.* 79:1240.

76. Cumano, A., and K. Rajewsky. 1986. Clonal recruitment and somatic mutation in the generation of immunological memory to the hapten NP. *EMBO (Eur. Mol. Biol. Organ.) J.* 5:2459.

77. Rajewsky, K., J. Förster, and A. Cumano. 1987. Evolutionary and somatic selection of the antibody repertoire in the mouse. *Science (Wash. DC.)* 238:1088.

78. Berek, C., and C. Milstein. 1988. The dynamic nature of the antibody repertoire. *Immunol. Rev.* 105:5.

79. Foote, J., and C. Milstein. 1991. Kinetic maturation of an immune response. *Nature (Lond.)* 352:530.

80. Clarke, S.H., K. Huppi, D. Ruzinsky, L. Staudt, W. Gerhard, and M. Weigert. 1985. Inter- and intracellular diversity in the antibody response to influenza hemagglutinin. *J. Exp. Med.* 161:687.

81. Abrahams, I., and T.G. Gilleran. 1960. Studies on actively acquired resistance to experimental cryptococcosis in mice. *J. Immunol.* 85:629.

82. Casadevall, A., J. Mukherjee, and M.D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococal polysaccharide. *J. Immun. Methods.* 154:27.

83. Spiropulu, C., R.A. Eppard, E. Otteson, and T.R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific to the capsular polysaccharide. *Infect. Immun.* 57:3240.

84. Sollazzo, M., C.A. Hasemann, K.D. Meek, D. Glotz, J.D. Capra, and M. Zanetti. 1989. Molecular characterization of the V, region of murine autoantibodies from neonatal and adult BALB/c mice. *Eur. J. Immunol.* 19:453.